Tor2 Inhibitors refer to a category of chemical compounds that target and inhibit the Tor2 protein, a key component of the Target of Rapamycin (TOR) pathway in yeast cells. This pathway is crucial for various cellular functions, including growth, proliferation, and survival. The TOR pathway senses and responds to a multitude of environmental cues, such as nutrient availability and growth factors, to coordinate these cellular processes. In the context of yeast, two TOR proteins exist: Tor1 and Tor2. These proteins form two distinct complexes, known as TORC1 and TORC2, with both playing unique roles in the cell. While TORC1 is more involved in nutrient signaling and growth, TORC2 is primarily concerned with maintaining cell wall integrity and actin organization.
Tor2 inhibitors specifically interfere with the functions of the Tor2 protein and, consequently, the broader TOR pathway. These chemical compounds act by binding to the Tor2 protein or its associated complexes, impeding it from carrying out its regular functions within the cell. The mechanisms of action can vary among the different inhibitors. Some inhibitors might directly block the kinase activity of Tor2, while others might disrupt the formation of the TOR complexes. Given the pivotal role of the TOR pathway in regulating various cellular functions, understanding and exploring the intricacies of Tor2 inhibitors offers insight into fundamental biological processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a selective inhibitor of mTOR kinase. By targeting the kinase domain of mTOR, it inhibits both TORC1 and TORC2 complexes, impacting Tor2 activity. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin1 is a potent ATP-competitive inhibitor of mTOR. It inhibits both TORC1 and TORC2, making it effective against the functions associated with Tor2. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU-0063794 is a specific mTOR inhibitor that affects both TORC1 and TORC2. It interferes with the kinase activity of mTOR, affecting Tor2 functions. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is an ATP-competitive mTOR inhibitor. It targets both TORC1 and TORC2, directly affecting the roles of Tor2 in the TOR pathway. | ||||||
WYE-125132 | 1144068-46-1 | sc-364651 sc-364651A | 10 mg 50 mg | $510.00 $1536.00 | ||
WYE-125132 is a potent and ATP-competitive mTOR inhibitor. It affects both TORC1 and TORC2, impacting the activities associated with Tor2. | ||||||
INK 128 | 1224844-38-5 | sc-364511 sc-364511A | 5 mg 50 mg | $321.00 $1835.00 | ||
INK128 is an mTOR kinase inhibitor. It targets both TORC1 and TORC2 complexes, making it effective against the functions of Tor2. | ||||||
Ridaforolimus | 572924-54-0 | sc-212783 | 5 mg | $248.00 | 1 | |
Ridaforolimus, also known as AP23573, is a derivative of rapamycin and acts as an mTOR inhibitor. It affects TORC1, which can indirectly influence the roles of Tor2. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is a derivative of rapamycin and acts by inhibiting mTOR. It primarily affects TORC1, which can have implications for Tor2 functions. | ||||||